Display options
Cite
Carter CA, Oronsky B, Caroen S, et al. Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC. Respir Med Case Rep. 2016;18:62-5doi: 10.1016/j.rmcr.2016.04.007.
Carter, C. A., Oronsky, B., Caroen, S., Scicinski, J., Cabrales, P., Degesys, A., & Brzezniak, C. (2016). Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC. Respiratory medicine case reports, 1862-5. https://doi.org/10.1016/j.rmcr.2016.04.007
Carter, Corey A, et al. "Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC." Respiratory medicine case reports vol. 18 (2016): 62-5. doi: https://doi.org/10.1016/j.rmcr.2016.04.007
Carter CA, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C. Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC. Respir Med Case Rep. 2016 Apr 24;18:62-5. doi: 10.1016/j.rmcr.2016.04.007. eCollection 2016. PMID: 27330954; PMCID: PMC4913156.
Copy Download .nbib Format: NLM
Share it on

Respir Med Case Rep. 2016 Apr 24;18:62-5. doi: 10.1016/j.rmcr.2016.04.007. eCollection 2016.

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Respiratory medicine case reports

Corey A Carter, Bryan Oronsky, Scott Caroen, Jan Scicinski, Pedro Cabrales, Aiste Degesys, Christina Brzezniak

Affiliations

  1. Walter Reed National Military Medical Center, Murtha Cancer Center, 8901 Wisconsin Ave, Bethesda, MD 20889, USA.
  2. EpicentRx, Inc., 800 W El Camino Real, Suite 180, Mountain View, CA 94040, USA.
  3. University of California San Diego, Dept of Bioengineering, 9500 Gilman Dr, La Jolla, CA 92093, USA.

PMID: 27330954 PMCID: PMC4913156 DOI: 10.1016/j.rmcr.2016.04.007

Abstract

Few therapeutic options are available for T790M-negative non-small cell lung cancer (NSCLC) after failure of primary epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy. This report presents the case of a 71-year-old Asian female never smoker with EGFR mutated T790M negative non squamous cell lung cancer (NSCLC) pre-treated with the experimental epi-immunotherapeutic agent, RRx-001, that re-responded to single agent carboplatin after failure of platinum doublets, TKIs, pemetrexed and nivolumab. The management of advanced EGFR mutation-positive NSCLC is briefly reviewed herein and the emerging paradigm of episensitization, which contradicts the long-standing and widely accepted tenet about the immutability of resistance and the futility of therapeutic rechallenge, is introduced as a strategy to avert treatment failure and thereby stave off deterioration and death.

Keywords: EGFR; Episensitization; NSCLC; RRx-001; T790 mutation

References

  1. N Engl J Med. 2009 Sep 3;361(10):958-67 - PubMed
  2. Nat Rev Clin Oncol. 2013 Oct;10(10):571-87 - PubMed
  3. Case Rep Oncol. 2014 Jan 24;7(1):79-85 - PubMed
  4. Case Rep Oncol. 2016 Jan 28;9(1):62-7 - PubMed
  5. Lancet Oncol. 2015 Aug;16(8):990-8 - PubMed
  6. Anticancer Agents Med Chem. 2014;14(8):1121-7 - PubMed
  7. Case Rep Oncol. 2016 Mar 11;9(1):171-6 - PubMed
  8. Oncotarget. 2015 Dec 22;6(41):43172-81 - PubMed
  9. J Clin Oncol. 2011 Aug 20;29(24):3307-15 - PubMed
  10. ACS Med Chem Lett. 2015 Dec 18;7(1):2-5 - PubMed
  11. J Clin Oncol. 2016 May 10;34(14):1676-88 - PubMed
  12. Oncologist. 2015 Nov;20(11):1230-2 - PubMed
  13. Bioorg Med Chem. 2008 Apr 1;16(7):3482-8 - PubMed
  14. Ann Oncol. 2016 Jun;27(6):1165-70 - PubMed
  15. Front Oncol. 2015 Jun 11;5:134 - PubMed
  16. N Engl J Med. 2005 Jul 14;353(2):123-32 - PubMed
  17. Ann Oncol. 2010 May;21 Suppl 5:v116-9 - PubMed
  18. Lancet Oncol. 2015 Sep;16(9):1013-5 - PubMed
  19. Cancer. 2013 Dec 15;119(24):4325-32 - PubMed

Publication Types